FOLH1 and prostate carcinoma: The first limitation in this study is that 68Ga-PSMA PET/CT may have limitation on detecting LNMs in the prostate cancer patients with negative PSMA expression (like neuroendocrine prostate cancer), although expression of PSMA has been recognized in approximately 95% of prostate cancer, both primary and metastatic (10, 41).